Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546182 | 0.92 | MAPT (0.44) | SMN1; SMN2MAPTTRPM8GAANPSR1 | |
| SCHEMBL6545462 | 0.83 | NPSR1 (0.40) | SMN1; SMN2MAPTTRPM8GAANPSR1 | |
| SCHEMBL11815554 | 0.66 | GAA (0.72) | SMN1; SMN2MAPTGAANPSR1POLB | |
| SCHEMBL6545090 | 0.65 | NQO1 (0.42) | SMN1; SMN2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL8421528 | 0.65 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPTGAANPSR1NPC1 | |
| SCHEMBL6546064 | 0.65 | RAB9A (0.44) | SMN1; SMN2MAPTGAANPC1RAB9A | |
| SCHEMBL6778438 | 0.63 | GAA (0.62) | SMN1; SMN2MAPTGAANPSR1POLB | |
| SCHEMBL7206841 | 0.63 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTGAAMEN1KMT2A | |
| SCHEMBL27460110 | 0.63 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTGAANPSR1POLB | |
| SCHEMBL6546178 | 0.62 | ALDH1A1 (0.41) | SMN1; SMN2MAPTGAANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379533-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | Leo Pharma A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| US-6605742-B2 | Rheumatic diseases; antiarthritic agents; antitumor agents | LEO PHARMA A/S (DK) | 2003-08-12 | — | — | US | disclosed |
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083696-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | CMA1, MMP9, CPA1 | SMN1; SMN2 4648/4885MAPT 4794/4885TRPM8 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.